These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15195528)

  • 21. Do we need yet another blocker of the renin-angiotensin system?
    Messerli FH; Re RN
    J Am Coll Cardiol; 2007 Mar; 49(11):1164-5. PubMed ID: 17367659
    [No Abstract]   [Full Text] [Related]  

  • 22. The relationship between liver function and portal pressure: what comes first, the chicken or the egg?
    Triantos C; Samonakis D; Thalheimer U; Patch D; Burroughs A
    J Hepatol; 2005 Jan; 42(1):146-7; author reply 147-8. PubMed ID: 15629521
    [No Abstract]   [Full Text] [Related]  

  • 23. [Circulatory dysfunction syndrome associated with liver cirrhosis].
    Hartleb M
    Przegl Epidemiol; 2005; 59(2):549-58. PubMed ID: 16190566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Portal hypertension: from pathophysiology to clinical practice.
    Laleman W; Landeghem L; Wilmer A; Fevery J; Nevens F
    Liver Int; 2005 Dec; 25(6):1079-90. PubMed ID: 16343056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breaking bad - the two sides of gut microbiota in portal hypertension.
    Mehta G; Mookerjee RP
    Liver Int; 2014 Oct; 34(9):1295-7. PubMed ID: 24840789
    [No Abstract]   [Full Text] [Related]  

  • 26. Preventing the development of varices in cirrhosis.
    Garcia-Tsao G
    J Clin Gastroenterol; 2007; 41 Suppl 3():S300-4. PubMed ID: 17975480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Aspects of pathogenetc pharmacotherapy for portal hypertension in liver cirrhosis].
    Garbuzenko DV
    Ter Arkh; 2016; 88(2):101-108. PubMed ID: 27135108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical therapy for portal hypertension in patients with cirrhosis in China: present situation and prospects.
    Zhou GW; Li HW
    Chin Med J (Engl); 2009 Jul; 122(13):1483-5. PubMed ID: 19719933
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel use of sildenafil in the treatment of portopulmonary hypertension.
    Chua R; Keogh A; Miyashita M
    J Heart Lung Transplant; 2005 Apr; 24(4):498-500. PubMed ID: 15797756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of intestinal microflora in the development of complications of hepatic cirrhosis-associated portal hypertension].
    Garbuzenko DV
    Klin Med (Mosk); 2007; 85(8):15-9. PubMed ID: 17926483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient elastography for diagnosis of portal hypertension in liver cirrhosis: is there still a role for hepatic venous pressure gradient measurement?
    Lim JK; Groszmann RJ
    Hepatology; 2007 May; 45(5):1087-90. PubMed ID: 17464984
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of endothelin in systemic and portal resistance in cirrhosis.
    Angus PW
    Gut; 2006 Sep; 55(9):1230-2. PubMed ID: 16905694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hemodynamic changes and its significance after liver transplantation for cirrhosis and portal hypertension].
    Zhang TL
    Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(22):1689-92. PubMed ID: 19094724
    [No Abstract]   [Full Text] [Related]  

  • 34. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
    Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
    Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The future treatment of portal hypertension.
    Reichen J; Lebrec D
    Best Pract Res Clin Gastroenterol; 2007; 21(1):191-202. PubMed ID: 17223505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension.
    Hernández-Guerra M; García-Pagán JC; Turnes J; Bellot P; Deulofeu R; Abraldes JG; Bosch J
    Hepatology; 2006 Mar; 43(3):485-91. PubMed ID: 16496307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Portal hypertension from the internal medicine viewpoint].
    Müting D; Fischer R; Ordnung W
    Chirurg; 1976 May; 47(5):253-9. PubMed ID: 1277959
    [No Abstract]   [Full Text] [Related]  

  • 38. Portopulmonary hypertension in cirrhosis: the pathogenetic challenge.
    Wong F
    Gut; 2005 Feb; 54(2):309. PubMed ID: 15647202
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension.
    Biecker E; Trebicka J; Kang A; Hennenberg M; Sauerbruch T; Heller J
    Liver Int; 2008 Mar; 28(3):331-8. PubMed ID: 18290775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis.
    Gatta A; Bolognesi M; Merkel C
    Mol Aspects Med; 2008; 29(1-2):119-29. PubMed ID: 18036654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.